PD-L1 antigen-binding protein and uses thereof

PD-L1 antigen binding proteins effectively address the limitations of current PD-1/PD-L1 inhibitors by enhancing tumor treatment through high-affinity binding, blocking interactions, and promoting T cell activation, achieving significant tumor volume reduction.

JP2024544386APending Publication Date: 2024-11-29SHANGHAI HUAOTA BIOPHARMACEUTICAL CO LTD +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024535386
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-15
Filing Date
2022-12-14
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Current PD-1/PD-L1 inhibitors have limited efficacy in treating tumors, particularly those with insufficient T cell infiltration, with an average clinical response rate of only 20-30%, indicating a need for improved treatment regimens.

Method used

Development of PD-L1 antigen binding proteins that can bind to PD-L1 with high affinity, block the PD-1/PD-L1 interaction, promote T cell activation, and inhibit tumor growth, utilizing isolated antigen binding proteins such as antibodies or fragments with specific CDR sequences.

Benefits of technology

The PD-L1 antigen binding proteins demonstrate enhanced tumor inhibition capabilities, including blocking PD-1/PD-L1 binding, promoting T cell activation, and reducing tumor volume, with clinical efficacy comparable to existing PD-1/PD-L1 inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544386000006
    Figure 2024544386000006
  • Figure 2024544386000007
    Figure 2024544386000007
  • Figure 2024544386000008
    Figure 2024544386000008
Patent Text Reader

Abstract

PD-L1 antigen binding proteins and uses thereof. The antigen binding proteins have one or more of the following properties: an EC of 0.07 μg / ml or higher 50 It can bind to PD-L1 protein at a specific concentration, block the binding between PD-L1 protein and PD-1 protein, promote the activation of T cells, and inhibit the increase in tumor volume in vivo. The application of antigen-binding proteins in the manufacture of drugs for treating tumors.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present application relates to the biomedicine field, in particular to PD-L1 antigen binding proteins and uses thereof. [Background technology]

[0002] Programmed cell death protein (PD-1) is a negative costimulatory molecule and a member of the CD28 immunoglobulin superfamily. PD-1 has two natural ligands, programmed death ligand 1 (PD-L1) and PD-L2. Here, PD-L1, also known as B7-H1, is an important negative immune regulator of PD-1, which mediates co-inhibitory signals for T cell activation by binding with PD-1, inhibiting T cell activation and proliferation, and inducing T cell apoptosis.

[0003] Immune regulation targeting PD-1 / PD-L1 has important implications for anti-tumor therapy. PD-L1 is overexpressed on the surface of various tumor cells, binds to PD-1 molecules on T cells, and induces apoptosis of T cells, thereby helping tumors escape the immune system. In recent years, 10 types of single antibody drugs targeting PD-1 or PD-L1 have been marketed one after another.

[0004] However, an increasing amount of clinical data shows that PD-1 / PD-L1 inhibitors are effective in "hot tumors" with sufficient infiltration of T cells, macrophages, etc., and the average clinical efficacy rate is between 20% and 30%, indicating that the indications and treatment plans of PD-L1 inhibitors still have room for improvement. Summary of the Invention

[0005] [Contents of the invention] The present application provides PD-L1 antigen binding proteins and uses thereof. According to one aspect, the present application provides an isolated antigen binding protein having one or more of the following properties: (1) EC of 0.07 μg / ml or higher 50 PD-L1 protein at a specific binding level; (2) blocking the binding between PD-L1 protein and PD-1 protein; (3) It can promote the activation of T cells; and (4) The ability to inhibit the increase in tumor volume in vivo.

[0006] In some embodiments, the isolated antigen binding protein comprises an antibody or an antigen-binding fragment thereof.

[0007] In some embodiments, the antigen-binding fragment comprises a Fab, a Fab', a F(ab)2, an Fv fragment, a F(ab')2, a scFv, a di-scFv, a VHH, and / or a dAb.

[0008] In some embodiments, the antibody is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a humanized antibody, and a fully human antibody.

[0009] In some embodiments, the isolated antigen binding protein competitively binds to the PD-L1 protein with a reference antibody comprising a heavy chain variable region, VH, and a light chain variable region, VL, wherein the VH of the reference antibody comprises HCDR1, HCDR2, and HCDR3, and the VL of the reference antibody comprises LCDR1, LCDR2, and LCDR3, and wherein HCDR1 of the reference antibody comprises the amino acid sequence set forth in SEQ ID NO: 1, HCDR2 of the reference antibody comprises the amino acid sequence set forth in SEQ ID NO: 21, HCDR3 of the reference antibody comprises the amino acid sequence set forth in SEQ ID NO: 22, LCDR1 of the reference antibody comprises the amino acid sequence set forth in SEQ ID NO: 6, LCDR2 of the reference antibody comprises the amino acid sequence set forth in SEQ ID NO: 23, and LCDR3 of the reference antibody comprises the amino acid sequence set forth in SEQ ID NO: 8.

[0010] In some embodiments, the isolated antigen binding protein comprises an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO:1.

[0011] In some embodiments, the isolated antigen binding protein comprises an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO:21.

[0012] In some embodiments, the isolated antigen binding protein comprises an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO:2 or 4.

[0013] In some embodiments, the isolated antigen binding protein comprises an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO:22.

[0014] In some embodiments, the isolated antigen binding protein comprises an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO:3 or 5.

[0015] In some embodiments, the isolated antigen binding protein comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:1, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:2, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:3; or wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 4, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 3; or wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 2, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 5; or Among them, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:1, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:4, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:5.

[0016] In some embodiments, the isolated antigen binding protein comprises a heavy chain variable region VH comprising the amino acid sequence set forth in any one of SEQ ID NOs:11-16.

[0017] In some embodiments, the isolated antigen binding protein comprises a heavy chain constant region derived from a human IgG constant region.

[0018] In some embodiments, the heavy chain constant region is derived from a human IgG1 constant region comprising the amino acid sequence set forth in SEQ ID NO:55.

[0019] In some embodiments, the isolated antigen binding protein comprises an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO:6.

[0020] In some embodiments, the isolated antigen binding protein comprises an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO:23.

[0021] In some embodiments, the isolated antigen binding protein comprises an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO:7, 9 or 10.

[0022] In some embodiments, the isolated antigen binding protein comprises an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO:8.

[0023] In some embodiments, the isolated antigen binding protein comprises LCDR1, LCDR2 and LCDR3, wherein the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:6, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:7, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:8; or wherein the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:6, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:9, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:8; or Among them, the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:6, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:10, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:8.

[0024] In some embodiments, the isolated antigen binding protein comprises a light chain variable region VL comprising the amino acid sequence set forth in any one of SEQ ID NOs: 17-20.

[0025] In some embodiments, the isolated antigen binding protein comprises an antibody light chain constant region comprising the amino acid sequence set forth in SEQ ID NO:56.

[0026] In some embodiments, the isolated antigen binding protein comprises a heavy chain variable region, VH, and a light chain variable region, VL, The VH comprises the amino acid sequence set forth in SEQ ID NO: 11, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 17; or The VH comprises the amino acid sequence set forth in SEQ ID NO: 12, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 18; or The VH comprises the amino acid sequence set forth in SEQ ID NO: 13, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 18; or The VH comprises the amino acid sequence set forth in SEQ ID NO: 14, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 18; or The VH comprises the amino acid sequence set forth in SEQ ID NO: 15, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 18; or The VH comprises the amino acid sequence set forth in SEQ ID NO: 16, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 18; or The VH comprises the amino acid sequence set forth in SEQ ID NO: 13, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 19; or The VH comprises the amino acid sequence set forth in SEQ ID NO: 14, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 19; or The VH comprises the amino acid sequence set forth in SEQ ID NO: 15, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 19; or The VH comprises the amino acid sequence set forth in SEQ ID NO: 16, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 19; or The VH comprises the amino acid sequence set forth in SEQ ID NO: 14, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 20; or The VH comprises the amino acid sequence set forth in SEQ ID NO: 15, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 20; or The VH comprises the amino acid sequence shown in SEQ ID NO:16, and the VL comprises the amino acid sequence shown in SEQ ID NO:20.

[0027] In another aspect, the present application provides a polypeptide comprising the isolated antigen binding protein.

[0028] In another aspect, the present application provides an immunoconjugate comprising said isolated antigen-binding protein or said polypeptide.

[0029] According to another aspect, the present application provides an isolated nucleic acid molecule or molecules encoding said isolated antigen binding protein.

[0030] In another aspect, the present application provides a carrier comprising the nucleic acid molecule.

[0031] In another aspect, the present application provides a cell comprising said nucleic acid molecule or said carrier.

[0032] According to another aspect, the present application provides a method of producing said isolated antigen binding protein, comprising culturing said cell under conditions allowing expression of said isolated antigen binding protein.

[0033] According to another aspect, the present application provides a pharmaceutical composition comprising said isolated antigen binding protein, said nucleic acid molecule, said carrier and / or said cell, and optionally a pharma- ceutically acceptable carrier.

[0034] In another aspect, the present application provides the use of said isolated antigen binding protein, said nucleic acid molecule, said carrier, said cell and / or said pharmaceutical composition in the manufacture of a medicament for use in the prevention, alleviation and / or treatment of a tumor.

[0035] According to another aspect, the present application provides a method of preventing, alleviating or treating a tumor, comprising administering said isolated antigen binding protein, said nucleic acid molecule, said carrier, said cell and / or said pharmaceutical composition to a subject in need thereof.

[0036] In another aspect, the present application provides said isolated antigen binding protein for use in the prevention, alleviation or treatment of tumors.

[0037] In some embodiments, the tumor comprises a tumor with high expression of PD-1 or PD-L1.

[0038] In some embodiments, the tumor comprises a solid tumor.

[0039] In some embodiments, the tumor comprises colon cancer.

[0040] In another aspect, the present application provides a method of inhibiting binding of PD-1 protein to PD-L1 protein comprising administering the isolated antigen binding protein and / or the polypeptide.

[0041] According to another aspect, the present application provides a method of promoting T cell activation comprising administering said isolated antigen binding protein and / or said polypeptide.

[0042] In another aspect, the present application provides a method for detecting the presence and / or content of PD-L1 protein comprising administering said isolated antigen binding protein and / or said polypeptide.

[0043] In another aspect, the present application provides a kit comprising the isolated antigen binding protein, the polypeptide, the immunoconjugate, the nucleic acid molecule, the carrier, the cell and / or the pharmaceutical composition.

[0044] Those skilled in the art can easily understand other aspects and advantages of the present application from the following detailed description. In the following detailed description, only exemplary embodiments of the present application are shown and described. As will be recognized by those skilled in the art, the contents of the present application may enable those skilled in the art to modify the specific embodiments disclosed without departing from the spirit and scope of the invention related to the present application. Correspondingly, the drawings and descriptions in the present application are illustrative only and not limiting. [Brief description of the drawings]

[0045] Particular features of the invention related to this application are set forth in the appended claims. A better understanding of the features and advantages of the invention related to this application can be obtained by reference to the exemplary embodiments and drawings described in detail below, which are briefly described as follows: [Figure 1] Blocking effect of candidate chimeric antibodies on the binding of free PD-1 to cell surface PD-L1. [Diagram 2] Shows the blocking effect of candidate chimeric antibodies on the binding of free PD-1 and cell surface PD-1. [Diagram 3] 1 shows the binding results of antigen binding proteins described herein to cell surface PD-L1. [Figure 4] 1 shows blockade of PD-1 / PD-L1 interaction by antigen binding proteins described herein. [Diagram 5] 1 shows the promotion of T cell activation by the antigen binding proteins described herein. [Figure 6]1 shows tumor volume following treatment of a mouse animal model with an antigen binding protein described herein. [Figure 7] 1 shows the weight change following treatment of a mouse animal model with an antigen binding protein described herein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0046] Hereinafter, the embodiments of the present invention will be described with reference to specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.

[0047] Definition of Terms In this application, the term "PD-L1" generally refers to the programmed death-ligand 1 protein. PD-L1 is also called cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), and is a protein encoded (in humans) by the CD274 gene. PD-L1 can bind to its receptors, such as programmed death 1 (PD-1). The complex of PD-L1 and PD-1 exerts an immunosuppressive effect by inhibiting T-cell proliferation and producing the cytokines IL-2 and IFN-γ. The term "PD-L1" encompasses any native PD-L1 or modified PD-1 from any vertebrate, including mammals such as primates (e.g., humans or monkeys) and rodents (e.g., mice or rats). The term includes "full-length," unprocessed PD-L1, and any form of PD-L1 produced by processing within cells. PD-L1 can exist as a transmembrane protein or a soluble protein. The term also includes naturally occurring variants of PD-L1, such as splice variants or allelic variants. The basic structure of PD-L1 includes four domains: an extracellular Ig-like V-type domain, an Ig-like C2-type domain, a transmembrane domain, and a cytoplasmic domain. PD-L1 sequences are known in the art. For example, information related to the human PD-L1 gene (including genomic DNA sequence) can be found at NCBI Gene ID No. 29126. The amino acid sequence of an exemplary full-length human PD-L1 protein can be found at NCBI Accession No. NP_054862 or UniProt Accession No. Q9NZQ7.

[0048] In this application, the term "antigen-binding protein" generally refers to a protein that includes an antigen-binding portion and, optionally, a scaffold or framework portion that allows the antigen-binding portion to adopt a conformation that promotes binding of the antigen-binding protein to an antigen. Antigen-binding proteins may typically include an antibody light chain variable region (VL), an antibody heavy chain variable region (VH), or both, and functional fragments thereof. The variable regions of the heavy and light chains include binding domains that interact with an antigen. Examples of antigen-binding proteins include, but are not limited to, antibodies, antigen-binding fragments, immune complexes, multispecific antibodies (e.g., bispecific antibodies), antibody fragments, antibody derivatives, antibody analogs, or fusion proteins, etc., so long as they exhibit the required antigen-binding activity.

[0049] In this application, the term "antibody" generally refers to an immunoglobulin that reacts with a specified protein or peptide or fragment thereof. The antibody may be of any type, including but not limited to IgG, IgA, IgM, IgD and IgE, and antibodies of any subclass (e.g., IgG1, IgG2, IgG3, and IgG4). The antibody may have a heavy chain constant region selected from, for example, IgG1, IgG2, IgG3, or IgG4. The antibody may also have a light chain selected from, for example, kappa (κ) or lambda (λ). The antibody of the present application may be of any species.

[0050] In this application, the term "antigen-binding fragment" generally refers to a portion of an antibody molecule that contains amino acid residues that interact with an antigen and confer specificity and affinity of the antibody for the antigen. Examples of antigen-binding fragments may include, but are not limited to, Fab, Fab', F(ab)2, Fv fragments, F(ab')2, scFv, di-scFv, and / or dAb. In this application, the term "Fab" generally refers to a fragment that contains a heavy chain variable domain and a light chain variable domain, as well as a constant domain of the light chain and the first constant domain (CH1) of the heavy chain. The term "Fab'" generally refers to a fragment that differs from Fab by the addition of a small number of residues (including one or more cysteines from the antibody hinge region) at the carboxy terminus of the heavy chain CH1 domain. The term "F(ab')2" generally refers to an antibody fragment that contains a dimer of Fab', two Fab fragments connected by disulfide bridges on the hinge region. The term "Fv" generally refers to the smallest antibody fragment that contains a complete antigen recognition and binding site. In some cases, the fragment may be composed of a dimer in which one heavy chain variable region and one light chain variable region are tightly non-covalently associated. The term "dsFv" generally refers to a disulfide-stabilized Fv fragment, in which the link between the single light chain variable region and the single heavy chain variable region is a disulfide bond. The term "dAb fragment" generally refers to an antibody fragment consisting of a VH domain. In this application, the term "scFv" generally refers to a monovalent molecule formed by covalently pairing one heavy chain variable domain and one light chain variable domain of an antibody via a flexible peptide linker, and such scFv molecules may have the general structure NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH.

[0051] In this application, the term "variable region" or "variable domain" generally refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. In this application, the term "variable" generally means that certain portions of the sequence of the variable domain of an antibody vary widely, resulting in the binding and specificity of different specific antibodies to specific antigens. The variability is not uniformly distributed throughout the variable region of an antibody. It is concentrated in three segments of the light and heavy chain variable regions called complementarity determining regions (CDRs) or hypervariable regions (HVRs), LCDR1, LCDR2, LCDR3, HCDR1, HCDR2 and HCDR3, respectively. The more highly conserved parts of the variable domain are called framework regions (FRs). Natural heavy and light chain variable domains each contain four FR regions (H-FR1, H-FR2, H-FR3, H-FR4, L-FR1, L-FR2, L-FR3, L-FR4), which mostly adopt a β-sheet structure and are connected by three CDR structural loop regions. The CDRs of each chain are held tightly together by the FR regions and, together with the CDRs of the other chain, form the antigen-binding site of antibodies.

[0052] In the art, the variable regions of an antibody can be encoded or the CDRs of an antibody can be divided by various methods, such as, for example, the Kabat numbering and definition rules based on sequence variability (see Kabat et al., Protein Sequence in Immunology, 5th ed., National Institutes of Health, Bethesda, MD (1991)), the Chothia numbering and definition rules based on the location of structural loop regions (see A1-Lazikani et al., J Mol Biol 273:927-48, 1997), the IMGT numbering and definition rules based on germline V gene-based amino acid sequence alignments of efranc et al., and the Honneger's numbering method (AHo's), Martin numbering method, Gelfand numbering method (see Mathieu Dondelinger et al., Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface / Residue Definition, Front. Immunol., 16 October 2018).

[0053] As used herein, the term "monoclonal antibody" generally refers to an antibody obtained from a population of essentially homogeneous antibodies, i.e., each antibody in the population is identical except for naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation), which may be present in very small amounts. Monoclonal antibodies are highly specific, targeting a single antigenic site.

[0054] In this application, the term "chimeric antibody" generally refers to an antibody whose variable region is derived from one species and whose constant region is derived from another species. Generally, the variable region is derived from an antibody of a laboratory animal such as a rodent (the "parent antibody"), and the constant region is derived from a human antibody, so that the resulting chimeric antibody is less likely to provoke a bad immune response in a human individual compared to the parent (e.g., mouse-derived) antibody.

[0055] In this application, the term "humanized antibody" generally refers to an antibody in which some or all amino acids outside the CDR regions of a non-human antibody (e.g., a murine antibody) are replaced with the corresponding amino acids derived from a human immunoglobulin. Addition, deletion, insertion, substitution or modification of amino acids in the CDR regions are also permitted as long as they retain the antibody's binding ability to a particular antigen. A humanized antibody may optionally contain at least a portion of a human immunoglobulin constant region. A "humanized antibody" retains similar antigen specificity as the original antibody. "Humanized" forms of non-human (e.g., murine) antibodies may be chimeric antibodies that contain minimal sequences derived from non-human immunoglobulin. In some cases, CDR region residues of a human immunoglobulin (acceptor antibody) can be replaced with CDR region residues of a non-human species (donor antibody) (such as mouse, rat, rabbit or non-human primate) having the desired properties, affinities and / or capabilities. In some cases, FR region residues of a human immunoglobulin can be replaced with the corresponding non-human residues. Humanized antibodies may also contain amino acid modifications that are not present in the recipient antibody or the donor antibody.

[0056] In the present application, the term "fully human antibody" generally refers to an antibody in which all parts (including the variable and constant regions of the antibody) are encoded by genes of human origin. Methods for obtaining fully human antibodies in the art may include phage display technology, transgenic mouse technology, ribosome display technology, and RNA-polypeptide technology.

[0057] In this application, the terms "binding", "specific binding" or "specific for" generally refer to an interaction that is both measurable and reproducible. For example, binding between an antigen and an antibody can determine the presence of a target in a heterogeneous population of molecules (including biomolecules). For example, an antibody binds to an epitope via its antigen-binding domain, or the binding requires a degree of complementarity between the antigen-binding domain and the epitope. For example, an antibody that specifically binds to a target (which may be an epitope) refers to an antibody that binds to this target with higher affinity, avidity, more readily, and / or with longer duration than other targets. If an antibody binds to an epitope via its antigen-binding domain more readily than a random, unrelated epitope that is bound, the antibody is said to "specifically bind" to that antigen.

[0058] In this application, the terms "polypeptide" or "protein" are used interchangeably and generally refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residues are analogs or mimetics of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The terms may also include amino acid polymers that have been modified, such as by the addition of sugar residues to form glycoproteins or by modification by phosphorylation. Polypeptides and proteins may be produced from naturally occurring and non-recombinant cells, or from genetically engineered or recombinant cells, and may include molecules having the amino acid sequence of a native protein or molecules with one or more amino acid deletions, additions and / or substitutions of the native sequence. The terms "polypeptide" and "protein" specifically include sequences with one or more amino acid deletions, additions and / or substitutions of the antigen binding proteins described herein.

[0059] In the present application, the term "homolog" generally refers to an amino acid sequence or a nucleotide sequence having a certain homology with a wild-type amino acid sequence and a wild-type nucleotide sequence. The term "homology" may be considered the same as sequence "identity". A homologous sequence may include an amino acid sequence that is at least 80%, 85%, 90%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to the subject sequence. In general, a homolog includes the same active site, etc. as the subject amino acid sequence. Homology may be considered in terms of similarity (i.e., amino acid residues having similar chemical properties / functions) or may be expressed in terms of sequence identity. In the present application, a sequence with a percentage identity to any one of the SEQ ID NOs of a referenced amino acid sequence or nucleotide sequence refers to a sequence with said percentage identity over the entire length of the referenced SEQ ID NO.

[0060] In this application, the term "isolated" generally refers to a biological material (e.g., a virus, a nucleic acid, or a protein) that is substantially free of components that are normally associated or interacting with it in its naturally occurring environment. The isolated biological material optionally includes other materials that are not found in the biological material in its natural environment (e.g., a nucleic acid or a protein). In this application, when referring to a protein, "isolated" generally means that the molecule is isolated and separated from a whole organism in which the molecule is found naturally, or is essentially free of other biological macromolecules of the same type. When referring to a nucleic acid molecule, it may be completely or partially isolated from sequences that are naturally associated with it, or the nucleic acid may have heterologous sequences associated with it, or the nucleic acid may be isolated from a chromosome.

[0061] As used herein, the term "immunoconjugate" generally refers to a substance formed by binding an antigen-binding protein to another active agent, which may be a small molecule active agent such as a chemotherapeutic agent, a toxin, an immunotherapeutic agent, an imaging probe, or a spectroscopic probe.

[0062] As used herein, the term "nucleic acid" molecule generally refers to an isolated form of nucleotides, deoxyribonucleotides or ribonucleotides or analogs thereof of any length, either isolated from their natural environment or artificially synthesized.

[0063] In this application, the term "carrier" generally refers to a nucleic acid molecule capable of self-replicating in a suitable host that transfers an inserted nucleic acid molecule into and / or between host cells. The carrier may include a carrier that is primarily used for inserting DNA or RNA into a cell, a carrier that is primarily used for replicating DNA or RNA, and a carrier that is primarily used for transcriptional and / or translational expression of DNA or RNA. The carrier further includes a carrier having various of the above functions. The carrier may be a polynucleotide that allows transcription and translation into a polypeptide when a suitable host cell is introduced. Generally, the carrier can produce a desired expression product by culturing a suitable host cell containing the carrier.

[0064] In the present application, the term "cell" generally refers to an individual cell, cell line, or cell culture that may contain or already contains a plasmid or carrier comprising a nucleic acid molecule described herein, or that is capable of expressing an antigen-binding protein described herein. The cell may include the progeny of a single host cell. Due to natural, accidental, or deliberate mutations, the progeny cell may not necessarily be completely morphologically or genomically identical to the original parent cell, but may be capable of expressing an antibody or antigen-binding fragment thereof described herein. The cell may be obtained by transfecting a cell in vitro using a carrier described herein. The cell may be a prokaryotic cell (e.g., E. coli) or a eukaryotic cell (e.g., a yeast cell, such as a COS cell, a Chinese hamster ovary (CHO) cell, a HeLa cell, a HEK293 cell, a COS-1 cell, a NS0 cell, or a myeloma cell). In some cases, the cell may be a mammalian cell. For example, the mammalian cell may be a CHO-K1 cell.

[0065] As used herein, the term "pharmaceutical composition" generally refers to a formulation in which the biological activity of an active ingredient is present in an acceptable and effective form and does not contain additional ingredients that are unacceptably toxic to a subject to which the composition is administered.

[0066] In this application, the term "treatment" generally refers to the desire to alter the natural history of the individual being treated, and may be a preventative or therapeutic clinical intervention in the course of a clinical disease. A met therapeutic effect includes, but is not limited to, preventing the onset or recurrence of a disease, alleviating symptoms, reducing any direct or indirect pathological consequences of a disease, preventing metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and alleviating or improving the prognosis. In some cases, the antigen binding proteins of the application (e.g., anti-PD-L1 antibodies) can be used to delay the onset of a disease or alleviate the progression of a disease.

[0067] As used herein, the term "administration" generally refers to a method of administering a dose of a compound (e.g., an anti-cancer therapeutic agent) or pharmaceutical composition (e.g., a pharmaceutical composition including an anti-cancer therapeutic agent) to a subject (e.g., a patient). Administration can be by any suitable method, including parenteral, intrapulmonary and intranasal, and (where localized treatment is required) intralesional administration. Parenteral administration includes, for example, intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.

[0068] As used herein, the term "tumor" generally refers to all neoplastic cell growth and proliferation (whether malignant or benign) and all pre-cancerous and cancerous cells and tissues. As used herein, the tumor may be a tumor with high expression of PD-1 or PD-L1 in cells and tissues. The tumor may include solid tumors and / or non-solid tumors.

[0069] In this application, the term "comprise" generally refers to the meaning of including, generalizing, containing, or encompassing. In some cases, it also refers to the meaning of "is" or "consists of."

[0070] In this application, the term "about" generally refers to a variation within 0.5% to 10% above and below a specified numerical value, for example, a variation of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below the specified numerical value.

[0071] Details of the invention In this application, mice are immunized four times with recombinantly expressed human PD-L1 protein as an antigen, and mouse spleen cells with high serum titers are isolated and fused with SP2 / 0 myeloma cells. Enzyme linked immunosorbent assay (ELSIA), fluorescence activated cell sorting (FACS), affinity measurement by surface plasmon resonance (SPR), and monoclonal seeding by limiting dilution are used to screen for monoclonal hybridoma cell lines expressing antibodies that specifically bind to PD-L1 antigen. Then, RNA is extracted from the candidate cell lines, reverse transcribed into cDNA, and the antibody heavy and light chain variable region genes are amplified by primer PCR method, and the gene sequences are obtained by sequencing. The same modeling is then used to compare with the database, and the original mouse sequence is mutated to human origin, and finally a highly humanized PD-L1 antigen binding protein with high biological activity and low immunogenicity is obtained.

[0072] PD-L1 antigen-binding protein According to one aspect, the present application provides an isolated antigen binding protein having one or more of the following properties: (1) capable of binding to PD-L1 protein with an EC50 value of 0.07 μg / ml or higher; (2) blocking the binding between PD-L1 protein and PD-1 protein; (3) It can promote the activation of T cells; and (4) The ability to inhibit the increase in tumor volume in vivo.

[0073] In the present application, the binding affinity to PD-L1 protein can be measured by any method known in the art, for example, surface plasmon resonance (SPR), enzyme-linked immunosorbent assay (ELISA), binding antigen precipitation, equilibrium dialysis, biolayer interference (BLI).

[0074] In the present application, the isolated antigen binding protein has an EC 50 For example, the EC 50 The value may be about 0.075 μg / ml or more, about 0.080 μg / ml or more, about 0.085 μg / ml or more, about 0.090 μg / ml or more, about 0.095 μg / ml or more, about 0.1 μg / ml or more, about 0.2 μg / ml or more, about 0.5 μg / ml or more, or about 1.0 μg / ml or more.

[0075] In the present application, the isolated antigen binding protein is 8×10 -11 M or lower. For example, a KD value of about 7.5×10 -11 M or less, about 7 x 10 -11 M or less, approximately 6×10 -11 M or less, about 5 x 10 -11 M or less, approximately 4 x 10 -11 M or less, about 3 x 10 -11 M or less, approximately 2×10 -11 M or less, approximately 1×10 -11 M or less, about 5 x 10 -12 M or less, approximately 1×10 -12 It can bind to human PD-L1 with the KD value of less than or equal to M, as detected, for example, by a FortieBio Octet molecular interaction analyzer.

[0076] In the present application, the isolated antigen binding protein can block the binding of PD-1 to PD-L1. For example, the blocking of the binding of PD-1 to PD-L1 by the antigen binding protein can be measured by flow cytometry (FACS) or enzyme-linked immunosorbent assay (ELISA).

[0077] For example, host cells (such as CHO-K1 cells) stably expressing human PD-L1 are first incubated with decreasing amounts of the antigen-binding protein that is unlabeled, and then incubated with biotin-labeled PD-1 protein. The cells are then analyzed using FACS to demonstrate blocking of the binding of PD-1 to PD-L1 by the antigen-binding protein. For example, between about 0.001 μg / mL and about 100 μg / mL, between about 0.001 μg / mL and about 10 μg / mL, between about 0.01 μg / mL and about 1 μg / mL, between about 0.01 μg / mL and about 1 μg / mL, between about 0.001 μg / mL and about 0.1 μg / mL.

[0078] In the present application, the isolated antigen binding protein can promote the activation of T cells. For example, the antigen binding protein can activate T cells capable of stably expressing human PD-1 (e.g., T cells capable of stably expressing human PD-1 and NFAT-inducible luciferase Jurkat) in the presence of target cells capable of expressing PD-L1 (e.g., the target cells can be CHO-K1-OS8-PD-L1-8D6 cells). The activation of the T cells can be obtained by detecting the full wavelength reading of a microplate reader for the T cells.

[0079] In the present application, the isolated antigen binding protein may include an antibody or an antigen binding fragment thereof.

[0080] In the present application, the antigen-binding fragment may include a Fab, a Fab', a F(ab)2, an Fv fragment, a F(ab')2, a scFv, a di-scFv, a VHH and / or a dAb. In the present application, the antibody is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a humanized antibody and a fully human antibody.

[0081] In the present application, the isolated antigen binding protein competitively binds to the PD-L1 protein with a reference antibody, wherein the reference antibody may comprise a heavy chain variable region, VH, and a light chain variable region, VL, wherein the VH of the reference antibody may comprise HCDR1, HCDR2, and HCDR3, wherein the VL of the reference antibody may comprise LCDR1, LCDR2, and LCDR3, and wherein HCDR1 of the reference antibody may comprise the amino acid sequence set forth in SEQ ID NO: 1, HCDR2 of the reference antibody may comprise the amino acid sequence set forth in SEQ ID NO: 22, HCDR3 of the reference antibody may comprise the amino acid sequence set forth in SEQ ID NO: 23, wherein LCDR1 of the reference antibody may comprise the amino acid sequence set forth in SEQ ID NO: 6, wherein LCDR2 of the reference antibody may comprise the amino acid sequence set forth in SEQ ID NO: 23, and wherein LCDR3 of the reference antibody may comprise the amino acid sequence set forth in SEQ ID NO: 8.

[0082] In the present application, the antigen binding protein is capable of competitive binding to the PD-L1 protein with the reference antibody, i.e., capable of competitively binding to at least a portion of the same PD-L1 epitope as the reference antibody.

[0083] In the present application, all of the CDR sequences are divided according to a specific CDR division standard (e.g., Kabat method). It should be noted that if the amino acid sequence of a PD-L1 antigen binding protein is divided according to a specific CDR division standard (e.g., Kabat method) to obtain CDRs that are the same as the CDR sequences of the present application, the amino acid sequence of the PD-L1 antigen binding protein is also included in the scope of the present application. Since the exact labeling of the CDR positions may differ slightly due to different CDR division standards, the present application not only includes the CDRs shown in the sequence listing, but also includes the CDRs contained in the VH and VL domains of other numbering systems. In addition, these VH and VL sequences can be used in scFv or Fab format.

[0084] In the present application, the PD-L1 antigen-binding protein has at least one of HCDRs 1 to 3 contained in a heavy chain variable region shown in any one of SEQ ID NOs: 11 to 16, and which are split in any CDR split form.

[0085] In the present application, the PD-L1 antigen-binding protein has at least one of LCDR1 to LCDR3, which is contained in a light chain variable region shown in any one of SEQ ID NOs: 17 to 20, and which is split in any CDR split form.

[0086] In the present application, the isolated antigen binding protein may comprise an HCDR1, and the HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1.

[0087] In the present application, the isolated antigen binding protein may comprise an HCDR2, and the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 21. The HCDR2 may comprise the amino acid sequence shown in WIYLGSGNAKYX1X2KFX3G (SEQ ID NO: 21), where X1 may be N or S, X2 may be E or Q, and X3 may be K or Q.

[0088] In the present application, the isolated antigen binding protein may comprise an HCDR2, and the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4.

[0089] In the present application, the isolated antigen binding protein may comprise an HCDR3, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 22. The HCDR3 may comprise the amino acid sequence shown in X1VGTYWYFDV (SEQ ID NO: 22), where X1 may be C or S.

[0090] In the present application, the isolated antigen binding protein may comprise an HCDR3, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 3 or 5.

[0091] In the present application, the isolated antigen binding protein may comprise HCDR1, HCDR2 and HCDR3, wherein the HCDR1 may comprise the amino acid sequence set forth in SEQ ID NO:1, the HCDR2 may comprise the amino acid sequence set forth in SEQ ID NO:2, and the HCDR3 may comprise the amino acid sequence set forth in SEQ ID NO:3, or wherein the HCDR1 may comprise the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 4, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 3, or wherein the HCDR1 may comprise the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 2, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 5, or Among them, the HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:4, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:5.

[0092] In the present application, the isolated antigen-binding protein may comprise H-FR1, the C-terminus of the H-FR1 being directly or indirectly linked to the N-terminus of the HCDR1, and the H-FR1 may comprise the amino acid sequence shown in SEQ ID NO: 48. For example, the H-FR1 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 24 to 27.

[0093] In the present application, the isolated antigen binding protein may comprise an H-FR2 located between the HCDR1 and the HCDR2, and the H-FR2 may comprise the amino acid sequence shown in SEQ ID NO: 49. For example, the H-FR2 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 28 to 29.

[0094] In the present application, the isolated antigen binding protein may comprise an H-FR3 located between the HCDR2 and the HCDR3, and the H-FR3 may comprise the amino acid sequence shown in SEQ ID NO: 50. For example, the H-FR2 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 30 to 33.

[0095] In the present application, the isolated antigen-binding protein may comprise H-FR4, the N-terminus of said H-FR4 being linked to the C-terminus of said HCDR3, and said H-FR4 may comprise the amino acid sequence shown in SEQ ID NO: 54. For example, said H-FR2 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 34 to 35.

[0096] In the present application, the H-FR1, H-FR2, H-FR3 and H-FR4 are (1) H-FR1: SEQ ID NO: 24, H-FR2: SEQ ID NO: 28, H-FR3: SEQ ID NO: 30, and H-FR4: SEQ ID NO: 34, or (2) H-FR1: SEQ ID NO: 25, H-FR2: SEQ ID NO: 29, H-FR3: SEQ ID NO: 31, and H-FR4: SEQ ID NO: 35, or (3) H-FR1: SEQ ID NO: 26, H-FR2: SEQ ID NO: 29, H-FR3: SEQ ID NO: 32, and H-FR4: SEQ ID NO: 35, or (4) H-FR1: selected from the group consisting of any of the amino acid sequences of SEQ ID NO: 27, H-FR2: SEQ ID NO: 29, H-FR3: SEQ ID NO: 33, and H-FR4: SEQ ID NO: 35.

[0097] In the present application, the isolated antigen-binding protein may comprise a heavy chain variable region VH, and the VH may comprise an amino acid sequence shown in any one of SEQ ID NOs: 11 to 16.

[0098] In the present application, the isolated antigen binding protein may comprise a heavy chain constant region, and the heavy chain constant region may be derived from IgG. For example, the heavy chain constant region may be derived from human IgG. The heavy chain constant region may be derived from IgG1, IgG2, IgG3 and IgG4. For example, the heavy chain constant region may be derived from human IgG1. For example, the human IgG1 constant region may comprise the amino acid sequence shown in SEQ ID NO:55.

[0099] In the present application, the isolated antigen binding protein may comprise LCDR1, and the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:6.

[0100] In the present application, the isolated antigen binding protein may comprise an LCDR2, and the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 23. The LCDR3 may comprise the amino acid sequence shown in DTSX1X2X3S (SEQ ID NO: 23), in which X1 may be N or S, X2 may be L or V, and X1 may be A or Q.

[0101] In the present application, the isolated antigen binding protein may comprise an LCDR2, and the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 7, 9 or 10.

[0102] In the present application, the isolated antigen binding protein may comprise an LCDR3, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:8.

[0103] In the present application, the isolated antigen binding protein may comprise LCDR1, LCDR2 and LCDR3, wherein the LCDR1 may comprise the amino acid sequence set forth in SEQ ID NO:6, the LCDR2 may comprise the amino acid sequence set forth in SEQ ID NO:7, and the LCDR3 may comprise the amino acid sequence set forth in SEQ ID NO:8, or Wherein, the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:6, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:9, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:8, or Among them, the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:6, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:10, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:8.

[0104] In the present application, the isolated antigen binding protein may comprise LCDR1, LCDR2 and LCDR3, and HCDR1, HCDR2 and HCDR3, wherein: The HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:2, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:3, and the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:6, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:7, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:8, or The HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:4, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:3, and the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:6, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:7, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:8, or The HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:2, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:5, the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:6, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:7, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:8, or The HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:4, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:5, the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:6, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:7, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:8, or The HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:2, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:3, the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:6, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:9, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:8, or The HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:4, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:3, the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:6, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:9, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:8, or The HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:2, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:5, the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:6, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:9, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:8, or The HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:4, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:5, the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:6, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:9, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:8, or The HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:4, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:3, the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:6, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:10, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:8, or The HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:2, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:5, the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:6, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:10, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:8, or The HCDR1 may comprise the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 4, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 5, and the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO: 6, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO: 10, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO: 8.

[0105] In the present application, the isolated antigen-binding protein may comprise L-FR1, the C-terminus of said L-FR1 being linked directly or indirectly to the N-terminus of said LCDR1, and said L-FR1 may comprise an amino acid sequence as set forth in any one of SEQ ID NOs: 36 to 38.

[0106] In the present application, the isolated antigen-binding protein may comprise an L-FR2 located between the LCDR1 and the LCDR2, and the L-FR2 may comprise the amino acid sequence shown in SEQ ID NO: 51. For example, the L-FR2 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 39 to 41.

[0107] In the present application, the isolated antigen-binding protein may comprise an L-FR3 located between the LCDR2 and the LCDR3, and the L-FR3 may comprise the amino acid sequence shown in SEQ ID NO: 52. For example, the L-FR2 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 42 to 45.

[0108] In the present application, the isolated antigen-binding protein may comprise an L-FR4, the N-terminus of which is linked to the C-terminus of the LCDR3, and the L-FR4 may comprise the amino acid sequence shown in SEQ ID NO: 53. For example, the L-FR2 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 46 to 47.

[0109] In the present application, the L-FR1, L-FR2, L-FR3 and L-FR4 are (1) L-FR1: SEQ ID NO: 36, L-FR2: SEQ ID NO: 39, L-FR3: SEQ ID NO: 42, and L-FR4: SEQ ID NO: 46, or (2) L-FR1: SEQ ID NO: 37, L-FR2: SEQ ID NO: 40, L-FR3: SEQ ID NO: 43, and L-FR4: SEQ ID NO: 47, or (3) L-FR1: SEQ ID NO: 38, L-FR2: SEQ ID NO: 40, L-FR3: SEQ ID NO: 44, and L-FR4: SEQ ID NO: 47, or (4) L-FR1: selected from the group consisting of any of the following amino acid sequences: SEQ ID NO: 38, L-FR2: SEQ ID NO: 41, L-FR3: SEQ ID NO: 45, and L-FR4: SEQ ID NO: 47.

[0110] In the present application, the isolated antigen-binding protein may comprise a light chain variable region VL, wherein the VL may comprise an amino acid sequence shown in any one of SEQ ID NOs: 17 to 20.

[0111] In the present application, the isolated antigen binding protein may comprise a light chain constant region, which may be derived from light chain lambda and light chain kappa. For example, the light chain constant region may comprise the amino acid sequence shown in SEQ ID NO:56.

[0112] In the present application, the isolated antigen binding protein may comprise a heavy chain variable region, VH, and a light chain variable region, VL, The VH may comprise the amino acid sequence set forth in SEQ ID NO: 11, and the VL may comprise the amino acid sequence set forth in SEQ ID NO: 17, or The VH may comprise the amino acid sequence set forth in SEQ ID NO: 12, and the VL may comprise the amino acid sequence set forth in SEQ ID NO: 18, or The VH may comprise the amino acid sequence set forth in SEQ ID NO: 13, and the VL may comprise the amino acid sequence set forth in SEQ ID NO: 18, or The VH may comprise the amino acid sequence set forth in SEQ ID NO: 14, and the VL may comprise the amino acid sequence set forth in SEQ ID NO: 18, or The VH may comprise the amino acid sequence set forth in SEQ ID NO: 15, and the VL may comprise the amino acid sequence set forth in SEQ ID NO: 18, or The VH may comprise the amino acid sequence set forth in SEQ ID NO: 16, and the VL may comprise the amino acid sequence set forth in SEQ ID NO: 18, or The VH may comprise the amino acid sequence set forth in SEQ ID NO: 13, and the VL may comprise the amino acid sequence set forth in SEQ ID NO: 19, or The VH may comprise the amino acid sequence set forth in SEQ ID NO: 14, and the VL may comprise the amino acid sequence set forth in SEQ ID NO: 19, or The VH may comprise the amino acid sequence set forth in SEQ ID NO: 15, and the VL may comprise the amino acid sequence set forth in SEQ ID NO: 19, or The VH may comprise the amino acid sequence set forth in SEQ ID NO: 16, and the VL may comprise the amino acid sequence set forth in SEQ ID NO: 19, or The VH may comprise the amino acid sequence set forth in SEQ ID NO: 14, and the VL may comprise the amino acid sequence set forth in SEQ ID NO: 20, or The VH may comprise the amino acid sequence set forth in SEQ ID NO: 15, and the VL may comprise the amino acid sequence set forth in SEQ ID NO: 20, or The VH may comprise the amino acid sequence shown in SEQ ID NO:16, and the VL may comprise the amino acid sequence shown in SEQ ID NO:20.

[0113] In the present application, the CDRs of the antigen-binding protein may be divided according to naming rules, for example according to the Kabat rules.

[0114] In the present application, a portion of each heavy or light chain amino acid sequence of the antigen binding protein is the same as the corresponding amino acid sequence of an antibody derived from a particular species or belongs to a particular type. For example, the variable and constant regions of the light and heavy chains are both the variable and constant regions of an antibody derived from one animal species (e.g., human). In the present application, the homologue may be a protein or polypeptide that has at least about 85% (e.g., at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more) sequence homology with the amino acid sequence of the protein and / or polypeptide (e.g., an antibody or fragment thereof that specifically binds to PD-L1 protein).

[0115] In this application, the homology generally refers to the similarity, resemblance or relationship between two or more sequences. Alignment to determine the percentage sequence homology can be achieved by various methods known in the art, such as using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment within the full length sequences being compared or within a sequence region of interest. The homology can also be measured by the methods FASTA and BLAST. For a description of the FASTA algorithm, see W. R. Pearson and D. J. Lipman, "An Improved Tool for Biological Sequence Comparison," Proc. Natl. Acad. Sci., 85:2444-2448, 1988, and D. J. Lipman and W. R. Pearson, "Fast and Sensitive Protein Similarity Searching," Science, 227:1435-1441, 1989. For a description of the BLAST algorithm, see S. Altschul, W. Gish, W. Miller, E. W. Myers and D. Lipman, "A Basic Local Alignment Search Tool," Journal of Molecular Biology, 215:403-410, 1990.

[0116] Detection Method The physical / chemical properties and / or biological activities of the PD-L1 antigen binding proteins described herein can be identified, screened or characterised by a variety of assays known in the art.

[0117] In one embodiment, the antigen-binding activity of the antigen-binding proteins of the present application can be tested by known methods, such as, for example, enzyme-linked immunosorbent assay (ELISA), immunoblot (e.g., Western blot), flow cytometry (e.g., FACS), immunohistochemistry, immunofluorescence, and the like.

[0118] Nucleic acids, carriers, host cells and production methods In another aspect, the present application further provides one or more isolated nucleic acid molecules. The one or more nucleic acid molecules can encode the antigen binding protein described herein. For example, each nucleic acid molecule in the one or more nucleic acid molecules can encode the entire antigen binding protein or a portion thereof (e.g., one or more of HCDR1-3, LCDR1-3, VL, VH, light chain, or heavy chain).

[0119] The nucleic acid molecules described herein may be isolated, for example, produced or synthesized by the following methods: (i) production by in vitro amplification, such as polymerase chain reaction (PCR) amplification, (ii) production by clonal recombination, (iii) purification by enzymatic cleavage and gel electrophoretic fractionation, or (iv) synthesis, such as chemical synthesis. In some embodiments, the isolated nucleic acid is a nucleic acid molecule produced by recombinant DNA technology.

[0120] In the present application, nucleic acids encoding the antibodies, antigen-binding fragments thereof, can be produced by a variety of methods known in the art, including, but not limited to, the use of restriction fragment manipulation or the use of overlap extension PCR with synthetic oligonucleotides.

[0121] In another aspect, the present application provides one or more carriers comprising one or more nucleic acid molecules described herein. Each type of carrier may comprise one or more of said nucleic acid molecules. The carrier may also comprise other genes, such as marker genes, that allow the selection of said carrier in a suitable host cell and under suitable conditions. The carrier may also further comprise expression control elements that allow the correct expression of the coding region in a suitable host. For example, the carrier is an expression carrier.

[0122] In another aspect, the present application provides host cells that may comprise one or more nucleic acid molecules described herein and / or one or more carriers described herein. In some embodiments, each or each host cell may comprise one or more nucleic acid molecules or carriers described herein. In some embodiments, each or each host cell may comprise multiple (e.g., two or more) or multiple (e.g., two or more) nucleic acid molecules or carriers described herein.

[0123] In another aspect, the present application provides a method for producing the antibody or antigen-binding fragment thereof. The method may comprise culturing the host cell described herein under conditions that allow expression of the antibody or antigen-binding fragment thereof. These methods will be understood by the skilled artisan, for example, by using an appropriate medium, appropriate temperature and incubation time.

[0124] Pharmaceutical Compositions, Methods and Uses In another aspect, the present application provides a pharmaceutical composition that may comprise the antigen-binding protein, the polypeptide, the nucleic acid molecule, the carrier, the host cell, and optionally a pharma- ceutically acceptable carrier described herein. The pharma- ceutically acceptable adjuvant is non-toxic to the recipient at the dosage and concentration used. The pharmaceutical composition herein may further comprise one or more active compounds, generally active compounds with complementary activities that do not adversely affect each other. The type and effective amount of such drugs will depend, for example, on the amount and type of antagonist present in the formulation, and on the clinical parameters of the subject.

[0125] The pharmaceutical compositions can be used to inhibit tumor growth, for example, the pharmaceutical compositions can inhibit or slow the onset or progression of a disease, reduce the size of a tumor (even essentially eliminate the tumor), and / or alleviate and / or stabilize a disease state.

[0126] The pharmaceutical compositions described herein may comprise a prophylactically and / or therapeutically effective amount of said antibody, antigen-binding fragment thereof, which is the amount necessary to prevent and / or treat (at least partially treat) a subject suffering from or at risk of developing a disease or condition and / or any complications thereof.

[0127] In another aspect, the present application provides a use of said antigen binding protein and / or said fusion protein in the manufacture of a medicament. The medicament is for use in treating cancer, inhibiting tumor growth and / or inhibiting tumor cell proliferation. In some embodiments, the tumor or cancer is a tumor or cancer with aberrant PD-L1 expression. In the present application, the tumor may comprise a tumor with high PD-1 or PD-L1 expression. In the present application, the tumor may comprise a tumor with high PD-L1 expression. In the present application, the tumor may comprise a solid tumor. In the present application, the tumor may comprise a colon cancer.

[0128] In another aspect, the present application provides a method of inhibiting binding of PD-L1 to PD-1, the method comprising administering an antigen binding protein and / or the polypeptide described herein. For example, the method may be an in vitro or ex vivo method. For example, the method may be a non-therapeutic method. In some cases, the method may comprise contacting a biological sample with an antigen binding protein and / or PD-L1 described herein under conditions that allow binding of the antigen binding protein and / or PD-1 to PD-L1, detecting whether a complex is formed between the antigen binding protein and PD-L1, and detecting whether a complex is formed between PD-1 and PD-L1.

[0129] In another aspect, the present application provides a method of promoting T cell activation, comprising administering said isolated antigen binding protein and / or said polypeptide. For example, the method may be an in vitro or ex vivo method. For example, the method may be a non-therapeutic method.

[0130] In another aspect, the present application provides a method for detecting the presence and / or content of PD-L1 protein, comprising administering said isolated antigen binding protein and / or said polypeptide. For example, the method may be an in vitro or ex vivo method. For example, the method may be a non-therapeutic method.

[0131] The present application further provides for the use of an antigen binding protein in a method for diagnosing a subject suffering from a tumor or cancer, the method comprising determining the presence or expression level of PD-L1 obtained from a subject sample by contacting the sample with an antigen binding protein of the application and detecting the presence of bound antibody.

[0132] According to another aspect, the present application provides a chimeric antigen receptor (CAR), which may comprise a nucleic acid molecule described herein or an antigen binding protein described herein.

[0133] In another aspect, the present application provides an antibody-drug conjugate, which may comprise the antigen-binding fragment.

[0134] In another aspect, the present application provides kits that may include the antigen binding proteins, chimeric antigen receptors, genetically modified cells, antibody drug conjugates, and / or pharmaceutical compositions described herein. A single common container may contain the antigen binding proteins, chimeric antigen receptors, genetically modified cells, and / or antibody drug conjugates described herein, optionally combined with one or more therapeutic agents, and optionally formulated into a pharmaceutical composition.

[0135] According to another aspect, the present application provides an administration device that can be used to administer the antigen binding protein or pharmaceutical composition thereof described herein.

[0136] Without intending to be limited by any theory, the following examples are merely illustrative of the antigen-binding proteins, production methods, and uses of the present application, and are not intended to limit the scope of the present invention.

[0137] Working Example Example 1. Screening of Monoclonal Antibodies 1.1 Animal immunization The primary immunization was performed on day 1, and the antigen was injected subcutaneously at multiple sites at a dose of 50μg / mouse. The antigen was recombinant human PD-L1 (product number: 10084-H08H, Sino Biological Inc.) protein emulsified with complete Freund's adjuvant (CFA). Three booster immunizations were then performed, and the titers of anti-PD-L1 antibodies in mouse serum were detected by ELISA method. Mice with relatively high antibody titers in serum were selected for splenocyte fusion.

[0138] 1.2 Hybridoma fusion and screening For hybridoma fusion, the spleens of four mice with relatively high titers were removed. The mouse spleens were ground into a cell suspension and red blood cells were removed, after which the splenic lymphocytes were mixed with the myeloma cells Sp2 / 0, and the splenic lymphocytes were fused with the myeloma cells Sp2 / 0 through an electric fusion device, and the splenic lymphocytes were added with a medium containing HAT for culture and screening, after which hybridoma cells were obtained. The initial screening of hybridoma cells was performed using antigen-antibody indirect ELSIA detection. 304 polyclonal cell lines were selected and monoclonalized using limiting dilution. After the cell clones were generated, the culture supernatants of the monoclonal cell lines were taken out, and the binding activity of human and rhesus PD-L1 was detected using the ELISA method, and the binding activity of ES-2 cells expressing PD-L1 was detected using a flow cytometer, from which cell lines with high binding activity were selected, and the affinity detection of the culture supernatants was further performed using Biacore, and finally 37 cell lines with high binding activity and high affinity were screened for antibody variable region gene clones.

[0139] 1.3 Preparation of anti-PD-L1 human-mouse chimeric antibody For the 37 clonal cell lines obtained by hybridoma screening, the total cellular RNA was first extracted using QIAGEN's RNA extraction kit (product number: 74106) according to the manufacturer's instructions, and then hybridoma cells containing the cDNA sequences expressing mouse antibodies were cloned by Takara's 5'rapid amplification of cDNA ends (5'RACE) technology. The antibody variable region sequences were then amplified by two rounds of PCR, and the PCR products were analyzed by agarose gel electrophoresis. The expected size of both the heavy and light chain variable region amplicons was approximately 500 base pairs. The amplified PCR products with the appropriate band size obtained by the reaction were cloned into the carrier pEASY-Blunt Simple vector (product number: CB111-02, Beijing Zenshi Jin Biological Technology Co., Ltd.) and transformed into Stellar E. coli competent cells (product number: 636763, Takara). Clones were screened by colony PCR with universal M13 forward or reverse primers, and 2-3 clones were selected from each reaction for DNA sequencing analysis. The results of each sequencing reaction for each clone were analyzed using the Expasy-translate tool (http: / / web.expasy.org / translate / ). Finally, 30 mouse monoclonal antibody variable region sequences were successfully extracted. For the 30 correct clones, heavy and light chain variable region genes were amplified by PCR and connected to a carrier containing a human IgG1 constant region sequence and a carrier with a human Igκ constant region sequence, respectively, to construct heavy chain expression carriers and light chain expression carriers of chimeric antibodies. Here, leucines at positions 234 and 235 (EU numbering system) of the heavy chain constant region CH2 were mutated to alanine to weaken the functional activities such as ADCC / CDC / ADCP mediated by the antibody Fc fragment. The expression carrier was mixed with polyetherimide (PEI) to form a liposome complex, which was then transfected into CHO-S cells (product number: R80007, SciFly China Co., Ltd.) and cultured for 7 days, after which the antibody was purified using a protein A affinity chromatography column.The resulting chimeric antibodies were assayed for in vitro and in vivo biological activity.

[0140] 1.4 Detection of PD-1 / PD-L1 blocking activity of anti-PD-L1 human-mouse chimeric antibodies Detecting the blocking activity of antibodies from two aspects: (1) To detect the blocking effect of antibodies on the binding between free PD-1 and cell surface PD-L1, CHO-K1-huPD-L1 cells overexpressing human PD-L1 were incubated with 2 × 10 4 The cells were seeded in a 96-well plate at 100 μl / well, and human PD-1-his tag (product number: 10377-H08H-100, Beijing Yiqiao Shenzhou Biological Technology Co., Ltd.) recombinant protein was diluted to 6 μg / mL with culture medium and added to the 96-well at 20 μl / well, mixed evenly, and incubated at room temperature for 30 min, and then 20 μl of the diluted sample to be measured was added, mixed evenly, and incubated at room temperature for 30 min. The cells were centrifuged at 300 g for 5 min, the supernatant was removed, the cells were washed twice with FACS buffer, and anti-his-dylight 488 (product number: ab117512, Abcam) secondary antibody was added after dilution at 1:500, mixed evenly, and incubated at room temperature for 15 min. After washing the cells three times, the fluorescence intensity of the cell surface was detected by the instrument, and the results are shown in Figure 1.

[0141] (2) Blocking the binding of free PD-L1 to cell surface PD-1 by antibodies was detected by incubating 2 × 10 CHO-K1-huPD-1 cells overexpressing human PD-1. 4The cells were seeded at 1:100 / well into a 96-well plate, and human PD-L1-moFc recombinant protein (SEQ ID NO:57) was diluted to 15μg / ml with culture medium and added to the 96-well at 20μl / well, mixed evenly, and incubated at room temperature for 15min, followed by adding 20μl of the diluted sample to be measured, mixed evenly, and incubated at room temperature for 15min. After centrifugation at 300g for 5min, the supernatant was removed, the cells were washed twice with FACS buffer, and Anti-moFc-alexa 488 (product number: 115-545-071, Jackson) secondary antibody was added after dilution at 1:300, mixed evenly, and incubated at room temperature for 15min. After washing the cells three times, the fluorescence intensity on the cell surface was detected by the instrument, and the results are shown in Figure 2.

[0142] In the blocking experiment, a lower detection value indicated a stronger blocking effect of the PD-L1 antibody. As can be seen from the results in Figures 1 and 2, the blocking effect of the 900245 antibody was the strongest and was non-inferior to the control antibody.

[0143] 1.5 Detection of anti-PD-L1 antibody affinity by SPR method Anti-Human Capture-CM5 chip (product number: BR-1005-30, GE) was prepared according to the Human Antibody Captrue Kit (product number: BR-1008-39, GE) and Amino Coupling Kit (product number: BR-1000-50, GE) coupling methods. The chip was equilibrated at room temperature for 20-30 min, and then installed in the Biacore 8K instrument. B5D1 was diluted to the experimental working concentration with equilibration buffer, and the antigen was diluted to 50 nM with equilibration buffer, and then further diluted 3-fold with a 7-concentration gradient. Two zero concentrations (i.e., equilibration buffer) and one repeat concentration (usually the lowest concentration repeat) were set. According to the regeneration order of the antibody, antigen huPD-L1 (product number: 10084-H08H, Sino Biological), 10 antigen concentrations (two zero concentrations, seven gradient concentrations, and one repeat concentration) were repeatedly analyzed in the experiment. The antigen injection flow rate was 30 μl / min, the binding time was 120 seconds, and the dissociation time was 600 seconds. After the analysis was completed, the corresponding analysis program was selected to analyze the data. After confirming that there was no obvious reference binding, the Kinetics, 1:1 binding model was selected to fit the data, and the kinetic-related parameters Ka, Kd, ​​and KD values ​​of the human-mouse chimeric antibody and the control antibody were obtained. The results are shown in Table 1. The chimeric antibody 900245 has a very strong affinity for the human PD-L1 antigen and is superior to control antibodies from other manufacturers (MDX 1105, Atezolizumab, Durvalumab and Avelumab, sequences disclosed by BMS, Roche, AstraZeneca and Pfizer, respectively, obtained by synthetic gene expression and purification).

[0144] [Table 1]

[0145] Example 2 Humanization of antibodies The variable regions of 900245 (VH: SEQ ID NO: 11, VL: SEQ ID NO: 17) were humanized and the mouse sequences were mutated to humanized sequences. The original heavy chain mVH sequence of the 900245 antibody was designed into 5 humanized sequences (huVH1, huVH2, huVH3, huVH4, huVH5), and the original light chain mVL of the 900245 antibody was designed into 3 humanized sequences (huVL1, huVL2, huVL3), and the 8 designed sequences were combined into 12 pairs of humanized antibodies to verify the subsequent expression. 900245 mouse variable region sequences: the underlined CDR regions (Kabat definition).

[0146] Of these, the amino acid sequences of huVH1-5 are shown in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16, respectively, and the amino acid sequences of huVL1-3 are shown in SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, respectively.

[0147] Five humanized heavy chain variable region genes were linked to a human IgG1 constant region gene (the amino acid sequence of which is shown in SEQ ID NO: 55), and three humanized light chain variable region genes were linked to a human Igκ constant region gene (the amino acid sequence of which is shown in SEQ ID NO: 56), and constructed into a pcDNA3.4 expression carrier, and the plasmid was transfected into ExpiCHO-s cells for transient expression. The protein was purified by Protein A, and then the binding activity was detected by ELISA and FACS, and the affinity was detected by SPR, and then the protein was screened, and the results were summarized in Table 2. Here, 900245Ab-H1L1 was a humanized antibody obtained by linking the above constant regions when VH was huVH1 and VL was huVL1.

[0148] [Table 2] TIFF2024544386000003.tif31170

[0149] The results showed that H5L1 (CoAD1445) had the highest binding activity and affinity, the highest degree of humanization, and the best expression purity and expression amount.The variable region genes of huVH5 and huVL1 were respectively constructed into antibody expression carriers and transiently transfected into CHO-S cells, and then expressed and cultured at 32℃ for 7 days. The supernatant was collected after centrifugation and purified using a Protein A affinity chromatography column to obtain humanized anti-PD-L1 antibody with no. 900760.

[0150] Example 3: Measurement of in vitro properties of humanized antibodies 3.1 Binding to cell surface PD-L1 antigen CHO-K1-huPD-L1 cells overexpressing human PD-L1 were cultured at 2 × 10 4 100μl / well of the cells were seeded in a 96-well plate, and 20μl / well of the sample to be measured, diluted in a 3-fold gradient series, was added and incubated with the cells at room temperature for 30min. After washing by centrifugation to remove unbound antibodies, 20μl of R-Phycoerythrin AffiniPure Goat Anti-Human IgG, Fcγ Fragment Specific (product number: 109-115-098, Jackson ImmunoResearch, diluted 1:200 in 1% (w / v) BSA-PBS) fluorescent secondary antibody was added to each well and incubated for 15min. The cells were then washed twice and resuspended in 100μl of 1% (w / v) BSA-PBS, and the fluorescence intensity was detected at 585nm with 488nm excitation by flow cytometry (BD, FACS Cantoll). The results are shown in Figure 3. The EC of humanized antibody 900760 and parent chimeric antibody was 100μl / well. 50 were 0.075 μg / ml and 0.125 μg / ml, respectively, and the EC 50 was 0.056 μg / ml, indicating that the binding activity of the humanized antibody to the antigen was high and close to that of the control antibody.

[0151] 3.2 Detection of affinity of humanized anti-PD-L1 antibodies using SPR method Anti-Human Capture-CM5 chip (product number: BR-1005-30, GE) was prepared according to the Human Antibody Captrue Kit (product number: BR-1008-39, GE) and Amino Coupling Kit (product number: BR-1000-50, GE) coupling methods. The chip was equilibrated at room temperature for 20-30 min, and then installed in a Biacore 8K instrument. B5D1 was diluted to an experimental working concentration with equilibration buffer, and the antigen was diluted to 50 nM with equilibration buffer, and then further diluted 3-fold with a 7-concentration gradient. Two zero concentrations (i.e., equilibration buffer) and one repeat concentration (usually the lowest concentration repeat) were set. According to the regeneration order of the antibody, antigen huPD-L1 (product number: 10084-H08H, Sino Biological), 10 antigen concentrations (two zero concentrations, seven gradient concentrations, and one repeat concentration) were repeatedly analyzed in the experiment. The antigen injection flow rate was 30 μl / min, the binding time was 120 seconds, and the dissociation time was 600 seconds. After the analysis was completed, the corresponding analysis program was selected to analyze the data. After confirming that there was no obvious reference binding, the Kinetics, 1:1 binding model was selected to fit the data, and the kinetic-related parameters Ka, Kd, ​​and KD values ​​of the humanized antibody and the control antibody were obtained. The results are shown in Table 3. The results showed that the humanized antibody 900760 has very strong affinity for the human PD-L1 antigen and is superior to the control antibody (Atezolizumab) from another manufacturer.

[0152] [Table 3]

[0153] 3.3 Effective blockade of PD-1 / PD-L1 interaction To detect the blocking effect of antibodies on the binding of free PD-L1 to cell surface PD-1, human PD-L1-moFc recombinant protein was diluted to 15μg / ml with culture medium and added to 96-well plates at 20μl / well. The antibody to be measured was diluted 3-fold gradient and then added to the above 96-well plate with antigen at 20μl / well, mixed evenly, and incubated at room temperature for 15min. CHO-K1-huPD-1 cells overexpressing human PD-1 were cultured at 2×10 4 The cells were added to the antigen-antibody pre-incubated 96-well plate at 1:100 / well, mixed evenly, and incubated at room temperature for 15 min. The cells were centrifuged at 300g for 5 min, the supernatant was removed, the cells were washed twice with FACS buffer, and Anti-moFc-Alexa 488 (product number: 115-545-071, Jackson) secondary antibody was added after dilution at 1:300, mixed evenly, and incubated at room temperature for 15 min. After washing the cells three times, the fluorescence intensity of the cell surface was detected by the instrument. The results are shown in Figure 4. The IC of humanized antibody 900760 and parent chimeric antibody 50 were 2.272 μg / ml and 2.838 μg / ml, respectively, and the IC 50 was 1.311 μg / ml, indicating that the humanized antibody well maintained its blocking activity on PD-1 / PD-L1 interaction and was close to that of the control antibody.

[0154] 3.4 Promotion of T cell activation The detection system consists of two genetically engineered cell lines: Jurkat-NFAT-PD-1-5B8 cells (PD-1 effector cells) are Jurkat T cells that stably express human PD-1 and NFAT-inducible luciferase, and CHO-K1-OS8-PD-L1-8D6 cells as target cells can stably express human PD-L1 and T cell activation antibody OKT3 single chain antibody on the cell surface. The detection antibody was diluted to 40 μg / ml in culture medium and then diluted two-fold in gradient for use. The effector cells Jurkat-NFAT-PD-1-5B8 were counted and counted at 5 × 10 5Count the target cells CHO-K1-OS8-PD-L1-8D6 and resuspend them at 5 × 10 / ml and seed them in a 96-well white bottom plate at 30 μl / well. 5 The plate was resuspended at 30 μl / well at 100 μl / ml, and the diluted sample to be measured was added at 30 μl / well. After mixing evenly, the plate was placed in a CO2 incubator and incubated at 37°C for 6 hours. After the incubation, the plate was equilibrated at room temperature for at least 15 minutes, and then the equilibrated Bio-Glo TM Luciferase Assay System reagent was added to a 96-well white plate at 90 μl / well, incubated at room temperature in the dark for 5 min, and all wavelengths were read on an MD SpectraMax® i3x microplate reader. Data was analyzed by fitting the RLU values ​​vs. antibody working concentration using a four-parameter equation in GraphPad Prism7 software. The results are shown in Figure 5. The EC values ​​of humanized antibody 900760 and parent chimeric antibody were 50 were 0.416 μg / ml and 0.287 μg / ml, respectively, and the EC 50 was 0.222 μg / ml, indicating that the humanized antibody of the present invention could effectively promote T cell activation, and the effect was comparable to that of the control antibody.

[0155] Example 4 In vivo antitumor activity of humanized antibodies To test the in vivo antitumor efficacy of anti-PD-L1 antibodies, a tumor model was established in which PD-L1-humanized MC38 colon cancer cell line (MC38-hPD-L1) was transplanted into PD-L1-humanized C57BL / 6J mice (hPD-L1-C57BL / 6J). The MC38-hPD-L1 cell suspension was inoculated subcutaneously on the right side of 6-8 week-old female mice, and the tumor volume size was approximately 100 mm. 3 When the animals reached 100%, they were divided into groups of 6 animals each and administration was started. Each group received intraperitoneal administration twice a week for three consecutive weeks, for a total of six times. Tumor diameters were measured twice a week, animals were weighed, and the animals' living conditions were observed and any abnormalities were recorded. Tumor volume (TV) was calculated as TV=1 / 2×a×b. 2where a represents the tumor long axis and b represents the tumor short axis. The tumor inhibition rate (TGI) of tumor volume was calculated as TGI=[1-(TVt-TVinitial) / (CVt-CVinitial)]×100%, where TVt represents the tumor volume of the treatment group at each measurement, TVinitial represents the tumor volume of the treatment group at group administration, CVt represents the tumor volume of the control group at each measurement, and CVinitial represents the tumor volume at group administration. Analysis was performed based on the original data, and the results were expressed as the mean number and standard deviation (Mean±SEM). T-test was used to analyze the difference in tumor volume between the control group and the treatment group, and p<0.05 indicated statistical difference.

[0156] As shown in Figures 6 and 7 below, the antitumor effect of humanized antibody 900760 was dose-dependent, and the tumor inhibition effect was close to the maximum when the dose reached 3mg / kg, with a TGI of 76.89%, close to the TGI of 78.15% in the 10mg / kg dose group (see Table 3), which was superior to the commercial control drug Tecentriq, which had a TGI of 69.69%. The weight of the mice in each group continued to increase steadily, and among them, the mice in the isotype negative control group were euthanized from day 17 due to the tumor volume being too large, which caused a large fluctuation in the data of this group.

[0157] [Table 4]

[0158] The foregoing detailed description is provided by way of illustration and example, and is not intended to limit the scope of the appended claims. Various variations of the presently recited embodiments will be apparent to those skilled in the art and are intended to remain within the scope of the appended claims and their equivalents.

Claims

1. An isolated antigen binding protein having one or more of the following properties: (1) EC of 0.07 μg / ml or higher 50 5. The ability of the antibody to bind to PD-L1 protein at a specific antibody value; (2) capable of blocking the binding between PD-L1 protein and PD-1 protein; (3) It is capable of promoting T cell activation; and (4) The ability to inhibit the increase in tumor volume in the body.

2. comprising an antibody or an antigen-binding fragment thereof, 2. The isolated antigen binding protein of claim 1.

3. The antigen-binding fragment comprises a Fab, a Fab', a F(ab)2, a Fv fragment, a F(ab')2, a scFv, a di-scFv, a VHH and / or a dAb.

3. The isolated antigen-binding protein of claim 2.

4. The antibody is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a humanized antibody, and a fully human antibody. The isolated antigen-binding protein of any one of claims 2 to 3.

5. competitively binds to the PD-L1 protein with a reference antibody comprising a heavy chain variable region VH and a light chain variable region VL, wherein the VH of the reference antibody comprises HCDR1, HCDR2, and HCDR3, the VL of the reference antibody comprises LCDR1, LCDR2, and LCDR3, and wherein the HCDR1 of the reference antibody comprises the amino acid sequence set forth in SEQ ID NO: 1, the HCDR2 of the reference antibody comprises the amino acid sequence set forth in SEQ ID NO: 21, the HCDR3 of the reference antibody comprises the amino acid sequence set forth in SEQ ID NO: 22, the LCDR1 of the reference antibody comprises the amino acid sequence set forth in SEQ ID NO: 6, the LCDR2 of the reference antibody comprises the amino acid sequence set forth in SEQ ID NO: 23, and the LCDR3 of the reference antibody comprises the amino acid sequence set forth in SEQ ID NO:

8. The isolated antigen-binding protein of any one of claims 1 to 4.

6. comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO:1; The isolated antigen-binding protein of any one of claims 1 to 5.

7. comprising an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO:21; The isolated antigen-binding protein of any one of claims 1 to 6.

8. comprising an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2 or 4; The isolated antigen-binding protein of any one of claims 1 to 7.

9. comprising an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO:22; 9. The isolated antigen-binding protein of any one of claims 1 to 8.

10. comprising an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 3 or 5; 10. The isolated antigen-binding protein of any one of claims 1 to 9.

11. comprising HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 2, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 3; or wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 4, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 3; or wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 2, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 5; or wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 4, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 5; The isolated antigen-binding protein of any one of claims 1 to 10.

12. The heavy chain variable region VH comprises an amino acid sequence represented by any one of SEQ ID NOs: 11 to 16; 12. The isolated antigen-binding protein of any one of claims 1 to 11.

13. comprising a heavy chain constant region derived from a human IgG constant region, 13. The isolated antigen-binding protein of any one of claims 1 to 12.

14. The heavy chain constant region is derived from a human IgG1 constant region comprising the amino acid sequence set forth in SEQ ID NO:

55.

14. The isolated antigen binding protein of claim 13.

15. comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO:6; 15. The isolated antigen binding protein of any one of claims 1 to 14.

16. comprising an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO:23; 16. The isolated antigen-binding protein of any one of claims 1 to 15.

17. comprising an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 7, 9 or 10; 17. The isolated antigen-binding protein of any one of claims 1 to 16.

18. comprising an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO:8; 18. The isolated antigen binding protein of any one of claims 1 to 17.

19. comprising LCDR1, LCDR2 and LCDR3, wherein the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:6, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:7, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:8; or wherein the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:6, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:9, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:8; or wherein the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:6, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:10, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:8; 19. The isolated antigen binding protein of any one of claims 1 to 18.

20. A light chain variable region VL comprising an amino acid sequence shown in any one of SEQ ID NOs: 17 to 20; 20. The isolated antigen binding protein of any one of claims 1 to 19.

21. comprising an antibody light chain constant region comprising the amino acid sequence set forth in SEQ ID NO:56; 21. The isolated antigen binding protein of any one of claims 1 to 20.

22. a heavy chain variable region VH and a light chain variable region VL, 1) the VH comprises the amino acid sequence set forth in SEQ ID NO: 11, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 17; or 2) the VH comprises the amino acid sequence set forth in SEQ ID NO: 12, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 18; or 3) the VH comprises the amino acid sequence set forth in SEQ ID NO: 13, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 18; or 4) the VH comprises the amino acid sequence set forth in SEQ ID NO: 14, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 18; or 5) the VH comprises the amino acid sequence set forth in SEQ ID NO: 15, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 18; or 6) the VH comprises the amino acid sequence set forth in SEQ ID NO: 16, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 18; or 7) the VH comprises the amino acid sequence set forth in SEQ ID NO: 13, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 19; or 8) the VH comprises the amino acid sequence set forth in SEQ ID NO: 14, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 19; or 9) the VH comprises the amino acid sequence shown in SEQ ID NO: 15, and the VL comprises the amino acid sequence shown in SEQ ID NO: 19; or 10) the VH comprises the amino acid sequence set forth in SEQ ID NO: 16, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 19; or 11) The VH comprises the amino acid sequence set forth in SEQ ID NO: 14, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 20; or 12) the VH comprises the amino acid sequence set forth in SEQ ID NO: 15, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 20; or 13) The VH comprises the amino acid sequence shown in SEQ ID NO: 16, and the VL comprises the amino acid sequence shown in SEQ ID NO: 20; 22. The isolated antigen binding protein of any one of claims 1 to 21.

23. A polypeptide comprising the isolated antigen-binding protein of any one of claims 1 to 22.

24. 24. An immunoconjugate comprising the isolated antigen-binding protein of any one of claims 1 to 22 or the polypeptide of claim 23.

25. 23. An isolated nucleic acid molecule or molecules encoding the isolated antigen binding protein of any one of claims 1 to 22.

26. A vector comprising the nucleic acid molecule of claim 25.

27. 27. A cell comprising the nucleic acid molecule of claim 25 or the vector of claim 26.

28. A method for producing the isolated antigen binding protein of any one of claims 1 to 22, comprising the steps of:

28. A method comprising culturing the cell of claim 27 under conditions allowing expression of the isolated antigen binding protein of any one of claims 1 to 22.

29. 28. A pharmaceutical composition comprising an isolated antigen binding protein according to any one of claims 1 to 22, a nucleic acid molecule according to claim 25, a vector according to claim 26 and / or a cell according to claim 27, optionally together with a pharma- ceutically acceptable carrier.

30. Use of an isolated antigen-binding protein according to any one of claims 1 to 22, a polypeptide according to claim 23, an immunoconjugate according to claim 24, a nucleic acid molecule according to claim 25, a vector according to claim 26, a cell according to claim 27 and / or a pharmaceutical composition according to claim 29, in The drug is used in the prevention, alleviation and / or treatment of tumors.

31. The tumor comprises a tumor with high expression of PD-1 or PD-L1.

31. The use according to claim 30.

32. The tumor comprises a solid tumor. Use according to any one of claims 30 to 31.

33. The tumor comprises colon cancer. Use according to any one of claims 30 to 32.

34. 1. A method for preventing, alleviating, or treating a tumor, comprising:

27. A method comprising administering to a subject in need thereof an isolated antigen-binding protein according to any one of claims 1 to 22, a polypeptide according to claim 23, an immunoconjugate according to claim 24, a nucleic acid molecule according to claim 25, a vector according to claim 26, a cell according to claim 27 and / or a pharmaceutical composition according to claim 29.

35. The tumor comprises a tumor with high expression of PD-1 or PD-L1.

35. The method of claim 34.

36. The tumor comprises a solid tumor.

36. The method according to any one of claims 34 to 35.

37. The tumor comprises colon cancer.

37. The method according to any one of claims 34 to 36.

38. 30. The isolated antigen-binding protein of any one of claims 1 to 22, the polypeptide of claim 23, the immunoconjugate of claim 24, the nucleic acid molecule of claim 25, the vector of claim 26, the cell of claim 27 and / or the pharmaceutical composition of claim 29 for use in the prevention, alleviation or treatment of a tumour.

39. A method for inhibiting binding between a PD-1 protein and a PD-L1 protein, comprising:

27. A method comprising administering an isolated antigen-binding protein according to any one of claims 1 to 22, a polypeptide according to claim 23, an immunoconjugate according to claim 24, a nucleic acid molecule according to claim 25, a vector according to claim 26, a cell according to claim 27 and / or a pharmaceutical composition according to claim 29.

40. 1. A method for promoting T cell activation, comprising:

27. A method comprising administering an isolated antigen-binding protein according to any one of claims 1 to 22, a polypeptide according to claim 23, an immunoconjugate according to claim 24, a nucleic acid molecule according to claim 25, a vector according to claim 26, a cell according to claim 27 and / or a pharmaceutical composition according to claim 29.

41. 1. A method for detecting the presence and / or content of PD-L1 protein, comprising:

24. A method comprising administering an isolated antigen binding protein according to any one of claims 1 to 22 and / or a polypeptide according to claim 23.

42. 27. A kit comprising an isolated antigen-binding protein according to any one of claims 1 to 22, a polypeptide according to claim 23, an immunoconjugate according to claim 24, a nucleic acid molecule according to claim 25, a vector according to claim 26, a cell according to claim 27 and / or a pharmaceutical composition according to claim 29.

Citation Information

Patent Citations

  • Anti-PD-l1 antibodies and uses thereof

    JP2017158553A